May 07, 2021
Article
Novavax plans to deliver approximately 350 million doses to COVAX during the third quarter of 2021.
The vaccine will now be included in WHO’s COVAX initiative, which is providing greater and more equitable access to vaccines around the world.
Reaching a vaccination rate of 50% by July of 2021 could prevent 5.8 million cases and 215,790 hospitalizations.
The companies are seeking approval for anyone aged 16 and above.
May 06, 2021
Company plans to initiate a rolling submission for US Food and Drug Administration (FDA) Biologics License Application (BLA) this month for the vaccine.
Moderna reports data demonstrating a single 50 µg shot of its mRNA-1273 or mRNA-1273.351 booster shot increased neutralizing titers against SARS-CoV-2, as well as the South African and Brazilian variants.
May 05, 2021
New real-world research suggest the vaccine may help provide control of the pandemic virus.
Amongst HIV negative participants, the vaccine demonstrated a 51% efficaciousness against B.1.351.
May 04, 2021
The company will provide the vaccine group with 34 million doses in the fourth quarter of this year, and up to 466 million more doses in 2022.
A report said the vaccine may receive a US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the 12-15 year old population as early as next week.
